ABSTRACT:In the present study, we investigated the esterase-like activity of human serum albumin (HSA) and the mechanism by which it hydrolyzes, and thereby activates, olmesartan medoxomil (CS-866), a novel angiotensin II receptor antagonist. CS-866 has previously been shown to be rapidly hydrolyzed in serum in which HSA appeared to play the most important role in catalyzing the hydrolysis. We found that the hydrolysis of CS-866 by HSA followed MichaelisMenten kinetics. Compared with the release of p-nitrophenol from p-nitrophenyl acetate (PNPA), CS-866 showed lower affinity to HSA and a lower catalytic rate of hydrolysis. Thermodynamic data indicated that PNPA has a smaller value of activation entropy (⌬S) than CS-866; consequently, PNPA is more reactive than CS-866. Ibuprofen and warfarin acted as competitive inhibitors of hydrolysis of CS-866, whereas dansyl-L-asparagine, n-butyl p-aminobenzoate, and diazepam did not. These findings suggest that the hydrolytic activity is associated to parts of site I and site II for ligand binding. All chemically modified HSA derivatives (Tyr-, Lys-, His-, and Trp-modifications) had significantly lower reactivity than native HSA; Lys-HSA and Trp-HSA had especially low reactivity. All the mutant HSAs tested (K199A, W214A, and Y411A) exhibited a significant decrease in reactivity, suggesting that Lys-199, Trp-214, and Tyr-411 play important roles in the hydrolysis. Results obtained using a computer docking model are in agreement with the experimental results, and strongly support the hypotheses that we derived from the experiments.Ester prodrugs are hydrolyzed to their pharmacologically active metabolites after absorption. Esterases present in the small intestine, plasma, and liver are involved in this process. In most cases, intestinal esterases serve as the major enzymes in activation of prodrugs during the first pass through the gut after absorption. However, prodrugs that are relatively resistant to hydrolysis by intestinal esterases enter the blood circulation and are activated by serum (plasma) and liver esterases. The major hydrolyzing enzymes in serum are cholinesterase, arylesterase, carboxylesterase, and albumin. The relative importance of each serum esterase in prodrug activation varies among animal species and prodrugs.Olmesartan medoxomil [CS-866: (5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxy-4-(1-hydroxyl-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)-phenyl]phenyl}methylimi-dazol-5-carboxylate] is a novel nonpeptide angiotensin II receptor antagonist that acts as an antihypertensive prodrug (Koike et al., 2001;Neutel, 2001;Brousil and Burke, 2003). After oral administration, CS-866 is rapidly de-esterified, producing an active acid metabolite, olmesartan (RNH-6270) ( Fig. 1) (Koike et al., 2001;Neutel, 2001;Brousil and Burke, 2003). Hydrolysis of CS-866 in serum has been observed in several species, and comparison among five species has shown that hydrolytic activity is highest in rabbits, followed by dogs, mice, rats, and humans (Ikeda, 2000). Furthermore, it was...